Sovateltide not checked

Pharmazz, Inc. · PMZ-1620 · SPI-1620

FollowEvery change as it happens, and a Monday email
Stage
in other
Next date
Phase 2 trial completes
Trials
5 active
10 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was…”In the company’s words, NCT05955326 on ClinicalTrials.gov
Tested for
Acute Cerebral Ischemia, Acute Ischemic Stroke, Cerebral Stroke, Traumatic Brain Injury, Acute Spinal Cord Injury, Hypoxic-Ischemic Encephalopathy, Neonatal Asphyxia, Neonatal Encephalopathy
Main trialPhase 4
“This is a prospective, multicenter, randomized, double-blind, parallel, phase IV study designed to evaluate the safety and efficacy of sovateltide (PMZ-1620, IRL-1620) as a potential treatment for cerebral ischemic stroke.”In the company’s words, NCT05955326 on ClinicalTrials.gov
Other names
PMZ-1620 · SPI-1620 · IRL-1620 · Tycamzzi · Tyvalzi

Other drugs for Acute Cerebral Ischemia

All 54 drugs for Acute Cerebral Ischemia

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 18 Dec 2026 Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Phase 3Recruiting Sep 2027 Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Phase 3Not yet recruiting Feb 2028 Sovateltide for the Treatment of Acute Traumatic Brain Injury
Phase 2Recruiting Jun 2026 PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
Phase 2Recruiting Nov 2026 Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
Phase 3Completed 10 Feb 2022 Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke
Phase 2Terminated Jul 2015 Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
Phase 2Terminated Sep 2015 Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Phase 2Completed 12 Apr 2019 PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients
Phase 2Completed 20 Dec 2022 PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Sovateltide

Following is part of Solo: you see every change to Sovateltide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in